Compare MMI & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMI | CERT |
|---|---|---|
| Founded | 1971 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2013 | 2020 |
| Metric | MMI | CERT |
|---|---|---|
| Price | $30.85 | $8.08 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $28.00 | $11.67 |
| AVG Volume (30 Days) | 107.2K | ★ 3.6M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.78% | N/A |
| EPS Growth | 84.38 | ★ 87.50 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $719,700,000.00 | $418,838,000.00 |
| Revenue This Year | $14.04 | $4.18 |
| Revenue Next Year | $11.35 | $5.39 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $24.43 | $4.45 |
| 52 Week High | $33.62 | $13.88 |
| Indicator | MMI | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 49.69 | 67.64 |
| Support Level | $29.72 | $6.57 |
| Resistance Level | $31.15 | $9.80 |
| Average True Range (ATR) | 0.77 | 0.33 |
| MACD | -0.03 | 0.05 |
| Stochastic Oscillator | 40.96 | 78.72 |
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans. The Company has one reportable segment: commercial real estate services. The commercial real estate services segment is the aggregation of our two operating segments: investment sales and financing services.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.